Citations (48)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Hassan H A-Kader. (2017) Lysosomal acid lipase deficiency: a form of non-obese fatty liver disease (NOFLD). Expert Review of Gastroenterology & Hepatology 11:10, pages 911-924.
Read now
Read now
Lars Aabakken. (2015) Scandinavian journal of gastroenterology – the editors-in-chief. Scandinavian Journal of Gastroenterology 50:6, pages 630-635.
Read now
Read now
Knut Boe Kielland, Ellen J. Amundsen & Olav Dalgard. (2014) HCV treatment uptake in people who have injected drugs — observations in a large cohort that received addiction treatment 1970–1984. Scandinavian Journal of Gastroenterology 49:12, pages 1465-1472.
Read now
Read now
Paola De Compadri, Daniela Koleva, Alessandra Mangia, Nicola Motterlini Stat Sci & Livio Garattini. (2008) Cost minimisation analysis of 12 or 24 weeks of peginterferon alfa-2b + ribavirin for hepatitis C virus. Journal of Medical Economics 11:1, pages 151-163.
Read now
Read now
Ligita Balciuniene, Tony Carlsson, Arvydas Ambrozaitis, Olle Reichard & Ola Weiland. (2003) Hepatitis C Virus RNA Levels During Initial Induction or Standard Interferon Therapy: Influence of Continued Treatment on Sustained Response. Scandinavian Journal of Infectious Diseases 35:3, pages 180-185.
Read now
Read now
Articles from other publishers (43)
Robert Whittaker, Jørgen E Midtbø & Hilde Kløvstad. (2024) Monitoring Progress Towards the Elimination of Hepatitis C as a Public Health Threat in Norway: A Modelling Study Among People Who Inject Drugs and Immigrants. The Journal of Infectious Diseases.
Crossref
Crossref
Annachiara Bellin, Giulia Franchin, Jenny Bolcato, Alessandra Bettiol, Roberta Pirolo, Alberto Schiavon, Pietro Giusti, Michele Tessarin & Alessandro Chinellato. (2019) Twenty Years of Hepatitis C in the Treviso District (Local Health Unit 2): Treatments, Clinical Management and Cost Analysis. Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish 2019, pages 228424031983586.
Crossref
Crossref
Akihito Tsubota, Tomomi Furihata, Yoshihiro Matsumoto & Kan Chiba. (2013) Sustained and rapid virological responses in hepatitis C clinical trials. Clinical Investigation 3:11, pages 1083-1093.
Crossref
Crossref
Mortada El-Shabrawi & Mona Isa. (2013) Commentary on: The optimal Dose of Ribavirin for Chronic Hepatitis C: From Literature Evidence to Clinical Practice. Hepatitis Monthly 13:2.
Crossref
Crossref
Alison A Murphy, Eva Herrmann, Anu O Osinusi, Lynn Wu, William Sachau, Richard A Lempicki, Jun Yang, Tei L Chung, Brad J Wood, Bart L Haagmans, Shyam Kottilil & Michael A Polis. (2011) Twice-weekly pegylated interferon-α-2a and ribavirin results in superior viral kinetics in HIV/hepatitis C virus co-infected patients compared to standard therapy. AIDS 25:9, pages 1179-1187.
Crossref
Crossref
T.J.S. Cross, A. Quaglia, J. Nolan, S. Hughes & P.M. Harrison. (2010) Do steatosis and steatohepatitis impact on sustained virological response (SVR) rates in patients receiving pegylated interferon and ribavirin for chronic hepatitis C infection?. Journal of Medical Virology 82:6, pages 958-964.
Crossref
Crossref
Timothy J. S. Cross, Mohammed M. Rashid, Philip A. Berry & Phillip M. Harrison. (2010) The importance of steatosis in chronic hepatitis C infection and its management: A review. Hepatology Research 40:3, pages 237-247.
Crossref
Crossref
Jesper Brok, Lise Lotte Gluud & Christian Gluud. (2010) Ribavirin plus interferon versus interferon for chronic hepatitis C. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Stuart K. Roberts, Martin D. Weltman, Darrell H. G. Crawford, Geoffrey W. McCaughan, William Sievert, Wendy S. Cheng, William Rawlinson, Paul V. Desmond, Phillipa S. Marks, Motoko Yoshihara, Bishoy Rizkalla, Jean K. DePamphilis & Gregory J. Dore. (2009) Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: A randomized controlled trial. Hepatology 50:4, pages 1045-1055.
Crossref
Crossref
Tomokazu Kawaoka, Yoshiiku Kawakami, Keiji Tsuji, Hiroyuki Ito, Mikiya Kitamoto, Shiomi Aimitsu, Hiroiku Kawakami, Soo Cheol Jeong, Michio Imamura, Hiroshi Aikata, Shoichi Takahashi & Kazuaki Chayama. (2009) Dose comparison study of pegylated interferon‐α‐2b plus ribavirin in naïve Japanese patients with hepatitis C virus genotype 2: A randomized clinical trial. Journal of Gastroenterology and Hepatology 24:3, pages 366-371.
Crossref
Crossref
Brian Bressler, Ka Wang, Joseph F. Grippo & E. Jenny Heathcote. (2009)
Pharmacokinetics and response of obese patients with chronic hepatitis C treated with different doses of PEG‐IFN α‐2a (40KD) (PEGASYS
®
)
. British Journal of Clinical Pharmacology 67:3, pages 280-287.
Crossref
Crossref
G. Esmat, Wafaa El Akel, M. Metwally, A. Soliman, W. Doss, M. Abdel Hamid, M. Kamal, K. Zalata, H. Khattab, M. El-Kassas, M. Esmat, A. Hasan & M. El-Raziky. (2009) Improvement of steatosis after interferon therapy in HCV genotype 4 is related to weight loss. Indian Journal of Gastroenterology 28:2, pages 45-48.
Crossref
Crossref
F. Negro. 2009. Liver under Constant Attack — From Fat to Viruses. Liver under Constant Attack — From Fat to Viruses
41
49
.
M. Alaei & F. Negro. (2008) Hepatitis C virus and glucose and lipid metabolism. Diabetes & Metabolism 34:6, pages 692-700.
Crossref
Crossref
Chien-Hua Chen, Shang-Tao Lin, Chi-Chieh Yang, Yung-Hsiang Yeh, Chien-Long Kuo & Chiu-Kue Nien. (2007) The Accuracy of Sonography in Predicting Steatosis and Fibrosis in Chronic Hepatitis C. Digestive Diseases and Sciences 53:6, pages 1699-1706.
Crossref
Crossref
Soocheol Jeong, Yoshiiku Kawakami, Mikiya Kitamoto, Hiroto Ishihara, Keiji Tsuji, Shiomi Aimitsu, Hiroiku Kawakami, Kiminori Uka, Shintaro Takaki, Hideaki Kodama, Koji Waki, Michio Imamura, Hiroshi Aikata, Shoichi Takahashi & Kazuaki Chayama. (2008) Prospective study of short‐term peginterferon‐α‐2a monotherapy in patients who had a virological response at 2 weeks after initiation of interferon therapy. Journal of Gastroenterology and Hepatology 23:4, pages 541-545.
Crossref
Crossref
Akihito Tsubota, Ken-ichi Satoh, Mashu Aizawa, Seishi Takamatsu, Yoshihisa Namiki, Toshifumi Ohkusa, Kiyotaka Fujise & Hisao Tajiri. (2008) Four-week pegylated interferon a-2a monotherapy for chronic hepatitis C with genotype 2 and low viral load: A pilot, randomized study. World Journal of Gastroenterology 14:47, pages 7220.
Crossref
Crossref
James Fung, Ching-Lung Lai & Man-Fung Yuen. 2008. Hepatitis C Virus Disease. Hepatitis C Virus Disease
130
147
.
Olav Dalgard, Kristian Bjøro, Helmer Ring-Larsen, Einar Bjornsson, Mona Holberg-Petersen, Eva Skovlund, Olle Reichard, Bjørn Myrvang, Bo Sundelöf, Ståle Ritland, Kjell Hellum, Aril Frydén, Jon Florholmen & Hans Verbaan. (2007) Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 47:1, pages 35-42.
Crossref
Crossref
Shotaro Enomoto, Hideyuki Tamai, Masashi Oka, Naoki Shingaki, Tatsuya Shiraki, Machiko Takeuchi, Hisanobu Deguchi, Hirohito Magari, Izumi Inoue, Mikitaka Iguchi, Kimihiko Yanaoka, Kenji Arii, Mitsuhiro Fujishiro, Naohisa Yahagi, Hiroshi Yotsuyanagi & Masao Ichinose. (2007) Potent induction therapy with interferon and ribavirin combination therapy does not achieve a higher sustained virological response rate in chronic hepatitis C with genotype 1b and high hepatitis C virus RNA level. Hepatology Research 37:9, pages 692-700.
Crossref
Crossref
Puneet Puri & Arun J. Sanyal. (2006) Role of Obesity, Insulin Resistance, and Steatosis in Hepatitis C Virus Infection. Clinics in Liver Disease 10:4, pages 793-819.
Crossref
Crossref
A. Andriulli, O. Dalgard, K. Bjøro & A. Mangia. (2006) Short-term treatment duration for HCV-2 and HCV-3 infected patients. Digestive and Liver Disease 38:10, pages 741-748.
Crossref
Crossref
Evangelos Cholongitas, Marco Senzolo, Richard Standish, Laura Marelli, Alberto Quaglia, David Patch, Amar P. Dhillon & Andrew Kenneth Burroughs. (2006) A Systematic Review of the Quality of Liver Biopsy Specimens. American Journal of Clinical Pathology 125:5, pages 710-721.
Crossref
Crossref
Olav Dalgard & Alessandra Mangia. (2006) Short-Term Therapy for Patients with Hepatitis C Virus Genotype??2??or??3 Infection. Drugs 66:14, pages 1807-1815.
Crossref
Crossref
Matthew J Hepburn, Jeffrey A Vos, Eric P Fillman & Eric J Lawitz. (2005) The accuracy of the report of hepatic steatosis on ultrasonography in patients infected with hepatitis C in a clinical setting: A retrospective observational study. BMC Gastroenterology 5:1.
Crossref
Crossref
M. GUIDI, P. MURATORI, A. GRANITO, L. MURATORI, G. PAPPAS, M. LENZI & F. B. BIANCHI. (2005) Hepatic steatosis in chronic hepatitis C: impact on response to anti‐viral treatment with peg‐interferon and ribavirin. Alimentary Pharmacology & Therapeutics 22:10, pages 943-949.
Crossref
Crossref
T. Carlsson, O. Reichard, G. Norkrans, J. Bläckberg, P. Sangfelt, E. Wallmark & O. Weiland. (2005) Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon‐alpha 2a and ribavirin according to virological response. Journal of Viral Hepatitis 12:5, pages 473-480.
Crossref
Crossref
P. Fabris, A. Floreani, A. Carlotto, V. Baldo, L. Bozzola, M. T. Giordani, F. Negro, M. Rassu, A. Tramarin & F. de Lalla. (2005) Impact of liver steatosis on virological response in elderly Italian patients with chronic hepatitis C treated with peg‐interferon alpha‐2b plus ribavarin. Alimentary Pharmacology & Therapeutics 21:9, pages 1173-1178.
Crossref
Crossref
Jesper Brok, Lise Lotte Gluud & Christian Gluud. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Norio Akuta, Fumitaka Suzuki, Yoshiyuki Suzuki, Hitomi Sezaki, Tetsuya Hosaka, Takashi Someya, Masahiro Kobayashi, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Mariko Kobayashi & Hiromitsu Kumada. (2005) Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients infected with HCV genotype 2a: Virological features of IFN‐resistant cases with hepatocyte steatosis. Journal of Medical Virology 75:4, pages 550-558.
Crossref
Crossref
Katalin Jármay. (2005) Changes in lipid metabolism in chronic hepatitis C. World Journal of Gastroenterology 11:41, pages 6422.
Crossref
Crossref
Olav Dalgard, Kristian Bjøro, Kjell Block Hellum, Bjørn Myrvang, Ståle Ritland, Kjell Skaug, Nils Raknerud & Helge Bell. (2004) Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: A pilot study. Hepatology 40:6, pages 1260-1265.
Crossref
Crossref
Andrew D. Clouston, Julie R. Jonsson & Elizabeth E. Powell. (2004) Chronic hepatitis C and steatosis. Current Hepatitis Reports 3:4, pages 123-128.
Crossref
Crossref
Stefan Zeuzem. (2004) Induction therapy in chronic hepatitis C: déjà-vu with pegylated interferons?. Journal of Hepatology 41:3, pages 488-490.
Crossref
Crossref
Rudolf E Stauber, Harald Hofer, Franz Hackl, Kurt Schüze, Christian Datz, Karin Hegenbarth, Wolfgang Jessner, Petra Steindl-Munda & Peter Ferenci. (2004) Retreatment of patients with chronic hepatitis C not responding to interferon/ribavirin combination therapy with daily interferon plus ribavirin plus amantadine. Wiener Klinische Wochenschrift 116:15-16, pages 530-535.
Crossref
Crossref
S. Engler, C. Flechtenmacher, K. H. Wiedemann, R. Gugler, W. Stremmel & B. Kallinowski. (2004) Interferon alfa2a induction therapy in combination with ribavirin and amantadine for the treatment of naive patients with chronic HCV infection. Journal of Viral Hepatitis 11:1, pages 60-68.
Crossref
Crossref
N. C. Tassopoulos, I. Ketikoglou, D. Tsantoulas, M. Raptopoulou, G. Hatzis, I. Vafiadis, L. Sidiropoulos, S. Kanatakis, G. Anagnostopoulos, V. Sypsa & A. Hatzakis. (2003) A randomized trial to assess the efficacy of interferon‐alpha daily in combination with ribavirin in the treatment of naïve patients with chronic hepatitis C. Journal of Viral Hepatitis 10:5, pages 383-389.
Crossref
Crossref
T Poynard. (2003) Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 38:1, pages 75-85.
Crossref
Crossref
J. M. Vrolijk, F. C. Bekkering, J. T. Brouwer, B. E. Hansen & S. W. Schalm. (2003) High sustained virological response in chronic hepatitis C by combining induction and prolonged maintenance therapy. Journal of Viral Hepatitis 10:3, pages 205-209.
Crossref
Crossref
Eva Merethe Moen, Solbjørg Sagedal, Kristian Bjøro, Miklos Degré, Per Kristian Opstad & Bjørn Grinde. (2003) Effect of immune modulation on TT virus (TTV) and TTV‐like‐mini‐virus (TLMV) viremia. Journal of Medical Virology 70:1, pages 177-182.
Crossref
Crossref
Elizabeth M. Brunt & Dina G. Tiniakos. (2002) Steatosis, steatohepatitis: Review of effects on chronic hepatitis C. Current Hepatitis Reports 1:1, pages 38-44.
Crossref
Crossref
Silvia Lee, Gerry C MacQuillan, Niamh M Keane, James Flexman, Gary P Jeffrey, Martyn AH French, Jean Brochier & Patricia Price. (2002) Immunological markers predicting outcome in patients with hepatitis C treated with interferon‐α and ribavirin. Immunology & Cell Biology 80:4, pages 391-397.
Crossref
Crossref
O. DALGARD, K. BJØRO, K. HELLUM, B. MYRVANG, T. BJØRO, E. HAUG & H. BELL. (2002) Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy. Journal of Internal Medicine 251:5, pages 400-406.
Crossref
Crossref